文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

目标温度管理36°C通过减轻失血性休克后有害炎症反应改善生存并保护组织

TARGETED TEMPERATURE MANAGEMENT AT 36°C IMPROVES SURVIVAL AND PROTECTS TISSUES BY MITIGATING THE DELETERIOUS INFLAMMATORY RESPONSE FOLLOWING HEMORRHAGIC SHOCK.
PubMed 文献 · Shock · 2024-08-23
一句话结论大鼠失血性休克模型显示,液体复苏后36°C目标温度管理改善生存并保护肺肾组织,而33°C目标温度管理反而增加死亡率。

本研究在大鼠失血性休克模型中,于液体复苏后分别实施33°C和36°C的目标温度管理(TTM),探讨其对炎症调控和器官保护的作用。结果显示,33°C TTM增加死亡率,而36°C TTM显著改善生存率,并减轻肺和肾组织的组织学损伤、降低血清乳酸水平、抑制细胞凋亡和过度活性氧产生。36°C TTM抑制HMGB1释放,降低肾和肺组织促炎细胞因子水平,并抑制有害的M1巨噬细胞表型、促进有益的M2极化。作者认为36°C TTM有望成为改善失血性休克结局的治疗策略。

要点

  • 大鼠失血性休克模型液体复苏后,36°C TTM显著改善生存率,而33°C TTM增加死亡率。
  • 36°C TTM减轻肺和肾组织学损伤,降低血清乳酸水平,抑制细胞凋亡和过度活性氧产生。
  • 36°C TTM抑制HMGB1释放,降低肾和肺组织促炎细胞因子水平(细胞因子阵列分析证实)。
  • 36°C TTM抑制有害的M1巨噬细胞表型、促进有益的M2极化。
  • 作者认为36°C TTM通过多环节调控损伤和炎症,可能降低失血性休克死亡率、改善患者恢复。

适用人群与场景

  • 大鼠失血性休克模型,在液体复苏后实施目标温度管理

处置流程与药物剂量

  • 液体复苏后实施36°C目标温度管理(TTM)
  • 液体复苏后实施33°C目标温度管理(TTM)

研究设计与关键结果

  • 研究类型:大鼠失血性休克模型实验;干预:液体复苏后实施33°C或36°C TTM;33°C TTM增加死亡率,36°C TTM显著改善生存率。
  • 36°C TTM减轻肺和肾组织组织学损伤,降低血清乳酸水平,抑制细胞凋亡和过度活性氧产生。
  • 36°C TTM抑制HMGB1释放,降低肾和肺组织促炎细胞因子水平;细胞因子阵列分析证实促炎细胞因子水平降低。
  • 36°C TTM抑制有害的M1巨噬细胞表型、促进有益的M2极化。

证据类型、等级与局限

  • 证据类型:动物实验(大鼠失血性休克模型)
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为36°C TTM有潜力作为改善失血性休克结局的治疗方法,可能降低死亡率并改善患者恢复。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Hemorrhagic shock (HS) is a life-threatening condition with high mortality rates despite current treatments. This study investigated whether targeted temperature management (TTM) could improve outcomes by modulating inflammation and protecting organs following HS. Using a rat model of HS, TTM was applied at 33°C and 36°C after fluid resuscitation. Surprisingly, TTM at 33°C increased mortality, while TTM at 36°C significantly improved survival rates. It also reduced histological damage in lung and kidney tissues, lowered serum lactate levels, and protected against apoptosis and excessive reactive oxygen species production. TTM at 36°C inhibited the release of high mobility group box 1 protein (HMGB1), a key mediator of inflammation, and decreased proinflammatory cytokine levels in the kidneys and lungs. Moreover, it influenced macrophage behavior, suppressing the harmful M1 phenotype while promoting the beneficial M2 polarization. Cytokine array analysis confirmed reduced levels of proinflammatory cytokines with TTM at 36°C. These results collectively highlight the potential of TTM at 36°C as a therapeutic approach to improve outcomes in HS. By addressing multiple aspects of injury and inflammation, including modulation of macrophage responses and cytokine profiles, TTM at 36°C offers promising implications for critical care management after HS, potentially reducing mortality and improving patient recovery.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Choi A, Woo JS, Park YS, et al. TARGETED TEMPERATURE MANAGEMENT AT 36°C IMPROVES SURVIVAL AND PROTECTS TISSUES BY MITIGATING THE DELETERIOUS INFLAMMATORY RESPONSE FOLLOWING HEMORRHAGIC SHOCK. Shock. 2024. PMID: 39186053. doi:10.1097/SHK.0000000000002453

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。